

BOARD OF DIRECTORS

: **Mr. ARUN KUMAR BHANGADIA**
Chairman- Promoter Non Executive

Mr. ARVIND KUMAR BHANGADIA
Managing Director

Mr. MURLIDHAR MUTGI
Independent Director

Mr. RAMSWAROOP AGRAWAL
Independent Director

Mr. ARUN KUMAR SARDA
Independent Director

REGISTERED OFFICE

: 4-4-231/1/2/ABC, Inderbagh,
Sultan Bazar, Hyderabad - 500 095.
Phone No. : 040-66662369
Fax No. : 040-24757370
E-mail : info@trimurthidrugs.com
website : www.trimurthidrugs.com

AUDITORS

: M/s. K. VENKATESWARA RAO & ASSOCIATES
Chartered Accountants
Flat No. 105, 1st Floor, Pooja Manor,
Himayathnagar, Hyderabad - 500 029.

BANKERS

: Axis Bank
ING Vysya Bank

REGISTRAR & SHARE TRANSFER AGENT : Venture Capital & Corporate Investments
Private Limited
12-10-167, Bharat Nagar, Hyderabad - 500 018
Ph.No: (040) 23818475 / 23818476

STOCK EXCHANGE (Listed/Traded)

: Bombay Stock Exchange Ltd.,
(BSE Indo Next-BSE Code 590093)
The Ahmedabad Stock Exchange Ltd.

DEMAT

: Central Depository Services (India) Ltd.,
National Securities Depository Limited

NOTICE

Notice is hereby given that the 16th Annual General Meeting of the Members of the Company will be held on Monday the 30th day of August, 2010 at 11.00 A.M. at RGA Hall, Snatak Bhavan, 5-4-790/1, Ashirvad Complex, 1st Floor, Abids, Hyderabad – 500 001, to transact the following Business:

ORDINARY BUSINESS :

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2010 and Profit and Loss Account for the year ended on that date and the Reports of the Directors and the Auditors thereon.
2. To declare dividend for the financial year ended 31st March, 2010.
3. To appoint Mr. Arun Kumar Bhangadia, Director who retires by rotation and being eligible, offers himself for reappointment.
4. To appoint Auditors who shall hold the office from the conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting and to fix their remuneration.

SPECIAL BUSINESS :

5. To consider and if thought fit, to pass with or without modifications, the following resolution as a Special resolution:

INCREASE IN REMUNERATION OF MANAGING DIRECTOR

“RESOLVED THAT as per the recommendations of the remunerations committee and pursuant to the provisions of Section 309 & Schedule XIII and other sections of the companies act 1956 Sri Arvind Kumar Bhangadia, Managing Director, be and is hereby paid a consolidated remuneration of Rs. 35000/- per month with effect from 01-09-2010.

6. To consider and if thought fit, to pass, with or without modifications, the following resolution, as a Special resolution:

CONSOLIDATION OF SHARE CAPITAL OF THE COMPANY

“RESOLVED THAT pursuant to section 94(1)(d) of the companies Act, 1956, the approval of the shareholders be and is hereby accorded to the consolidation of existing authorised share capital of 7,00,00,000 equity shares of Rs.1/- each fully paid up into 70,00,000 equity shares of Rs.10/- each fully paid up & consolidation of existing paid up share capital of 6,75,00,000 equity shares of Rs. 1/- each fully paid up in to 67,50,000 equity shares of Rs. 10/- each.

RESOLVED FURTHER That clause V of Memorandum of Association and article 4 of Articles of Association be altered accordingly.

“RESOLVED FURTHER That Mr. Arvind Kumar Bhangadia, Managing Director of the Company be and is hereby authorised to file the necessary forms/returns with the Registrar of Companies and make an application to Ahmedabad Stock Exchange and Bombay Stock Exchange for Permission to deal in and for official quotation for 70,00,000 Equity shares of Rs. 10/-each and also to inform all statutory authorities wherever the same is required.”

7. To consider and if thought fit, to pass the following resolution with or without any modifications as a Special Resolution.

INCREASE OF AUTHORISED SHARE CAPITAL OF THE COMPANY:

RESOLVED THAT pursuant to Section 97 of the Companies Act, 1956 and other applicable provisions if any of the Act, the Authorised Share Capital of the Company be and is hereby increased from Rs. 7,00,00,000/- (Rupees Seven Crores Only) divided into 70,00,000 (Seventy Lakhs Only) Equity Shares of Rs. 10/- (Rupees Ten Only) each to Rs.20,00,00,000/- (Rupees Twenty Crores Only) divided into 200,00,000 (Two Crore Only) Equity Shares of Rs. 10/- (Rupees Ten only) each by creating further 1,30,00,000 (One Crore Thirty Lakhs only) Equity Shares of Rs.10/- (Rupees Ten Only) each ranking pari passu with the existing equity shares of the Company”.

8. To consider and if thought fit, to pass with or without modification(s) the following resolution as an Ordinary resolution.

AMENDMENT OF THE CLAUSE V OF THE MEMORANDUM OF ASSOCIATION:

“RESOLVED THAT pursuant to Section 16 and other applicable provisions, if any, of the Companies Act, 1956, the existing clause V of the Memorandum of Association relating to the Share Capital be and is hereby altered by deleting the same and substituting in its place, the following Clause V.

“The authorized share capital of the Company is Rs.20,00,00,000/- (Rupees Twenty Crores Only) divided into 200,00,000 (Two Crores Only) Equity Shares of Rs. 10/- (Rupees Ten only) each. The Company has power from time to time to increase or reduce its capital and issue any shares in the original unclassified or new capital as equity or preference shares and to attach to any class of shares any preferences, rights, privileges or priorities in payment of dividends or distribution of assets or otherwise over any other shares or to subject the same to any restrictions, limitations or conditions, and to vary the regulations of the Company, as far as necessary to give effect to the same and upon the sub-division of a share to apportion the right to participate in profits in any manner subject to the prior consent of the authorities concerned, if any.

9. To consider and if thought fit, to pass with or without modification(s) the following resolution as a Special resolution.

AMENDMENT OF THE ARTICLE- 4 OF THE ARTICLES OF ASSOCIATION:

“RESOLVED THAT pursuant to Section 31 and other applicable provisions, if any, of the Companies Act, 1956, the existing Article 4 of the Articles of Association relating to the Share Capital be and is hereby altered by deleting the same and substituting in its place and stead, the following Clause 4”

“The Authorized Share Capital of the Company is Rs.20,00,00,000/- (Rupees Twenty Crores Only) divided into 200,00,000 (Two Crore Only) Equity Shares of Rs. 10/- (Rupees Ten only) each with rights, privileges annexed thereto and upon such terms and conditions as may be fixed in the General Meeting, sanctioning the issue of the such Shares, be directed and if such direction given and all other cases, as the Board shall determine.”

10. To consider and if thought fit, to pass with or without modification(s) the following resolution as a Special resolution.

AMENDMENT OF OTHER OBJECTS:

“RESOLVED THAT pursuant to Section 17 of the Companies Act, 1956 and other applicable provisions if any of the Act, and subject to the approval of the Registrar of Companies and subject to such conditions and modifications as may be prescribed by the appropriate authorities in granting such approvals, the other Objects clause of the Company be and is amended by adding the following objects after the existing other objects clause 12 and the new clause read as under

13. To carryout in India or elsewhere the business to manufacture, produce, process, fabricate, market, convert, commercialize, grade, develop, design, press, stitch, mould, flex, export, import, job work, buy, sell, stretch, stamp, shape, smelt, emboss, print, laminate, and to act as agent, broker, adatia, consultant, advisor, representative, franchiser, stockiest, distributor or otherwise deal in all shapes, sizes, varieties, capacities, descriptions and dimensions of packing material and its allied products whether made of wood, plywood, thermo Cole, wood wool, particle board, corrugated paper, craft paper, rubber, strawboards, cardboards, aluminum foils, metal foils, glass, plastics, gelatin, bakelite, polypropylene and its compounds, tin, iron sheets, jute, synthetic material, cloths and other ferrous and non ferrous materials.
14. To generate, harness, develop, purchase, accumulate, trade, distribute, and supply electricity by setting up hydro, thermal and other power plants using liquid, gaseous or solid fuels like water, gas, air, naphtha, coal, diesel oil and other petroleum products, or through renewable energy sources such as solar, photo voltaic, wind mill or through any other means and to supply such power either directly or through transmission lines and such other facilities of the Central or State Governments or Private Companies or Electricity Boards to Industries and to Central/State Government, Electricity Boards and other consumers and to achieve the objectives referred to above either singly or in joint venture with partners, Indian or foreign or through third parties, whether Indian or foreign on a turnkey basis and to transmit, distribute, supply and sell power to Central/State Government, Electricity Boards, Industry and other consumers, whether within the state or otherwise of electricity including those for captive consumption and to provide operate and maintain facilities relating to electric and all other kinds of power generation projects including among other things responsibility for day to day operations, routine maintenance and management of facilities.
15. To Transmit, distribute, purchase, sell, trade, import , export or accumulate or otherwise deal in all forms of electrical power in all aspects and to plan, promote, develop,

establish transmission and distribution networks or systems, trading platforms and to acquire, in any manner, these networks or systems or trading platforms and to acquire, in any manner, these networks or systems or trading platforms from power generating and transmission companies, Central or State Government undertakings, local authorities or statutory bodies or other persons within India or abroad.

11. To consider and if thought fit, to pass with or without modification(s) the following resolution as a Special resolution.

AUTHORISATION FOR FUND RAISING:

“RESOLVED THAT pursuant to the provisions of 81(1A) and other applicable provisions, if any, of the Companies Act, 1956 (including any amendments thereto or re-enactment thereof,) (the Act) the provisions of the Foreign Exchange Management Act, 2000, as amended, Ordinary Shares (through Depository Receipt Mechanism) Scheme, 1993, (including any amendment thereto), Foreign Exchange Management (Transfer or issue of any Foreign Security) Regulations, 2004 (including any amendment thereto), Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended (“SEBI ICDR Regulations”) and in accordance with the rules, regulations, guidelines, notifications, circulars and clarifications issued thereon from time to time Government of India (“GOI”) the Reserve Bank of India (“RBI”) the Securities and Exchange Bank of India (“SEBI”) and/or any other competent authorities (including any amendment thereto or re-enactment thereof for the time being in force) and the enabling provisions of the Memorandum and Articles of Association of the Company, the listing agreements entered into by the company with the stock exchanges on which the company’s shares are listed and subject to necessary approvals, permissions, consents and sanctions of financial institutions, lenders statutory and other appropriate and/or relevant/concerned authorities and subject to such conditions and modifications as may be prescribed by any of them while granting such, approvals, permissions, consents and sanctions which may be agreed to by the Board of Directors of the Company (hereinafter referred to as the “Board”, which term shall include committee thereof), consent of the company be and is hereby accorded to the board to create, offer, issue and allot (including with provisions for reservation on firm and/or competitive basis, of such part of issue and for such categories of person including employees of the Company as may be permitted), and/or Global Depository Shares (GDSs) and/or Global Depository Receipts (GDRs) and/or securities convertible into equity shares, and/or Foreign Currency Convertible Bonds (FCCBs) representing Equity

shares and/or Debentures or Bonds convertible into equity shares whether fully or partly and whether compulsorily or at the option of the Company or the holders thereof and/or any security linked to equity shares and/or Preference Shares whether cumulative/fully convertible and/or all or any of the aforesaid securities with or without detachable or non-detachable warrants, as the Company may be advises (all of which are hereinafter collectively referred to as "Securities") or any combination thereof, whether secured by way of charge on the assets of the company or unsecured as may be decided by the Board, in one or more trenches, of public and/or private offerings and/or qualified institutional placements and/or on preferential allotment basis or any combination thereof through issue of prospectus and/or placement document and/or other permissible/ requisite offer document, to eligible resident or non-resident/foreign investors (whether institutions and/or incorporated bodies and/or individuals and/or trusts and/or otherwise)/Foreign institutional investors (FIIS)/ Qualified institutional buyers (QIBs)/Foreign Corporate Bodies (FCBs) Foreign Companies/Mutual Funds/Pension Funds/Venture Capital Funds/Banks; Indian or of Foreign origin and such other persons or entities, including the general public whether or not such investors are members of the Company, to all or any of them. Jointly or severally to be subscribed in Indian and/or Foreign Currency(ies) through prospectus, offering letter circular, memorandum and/or through any other mode as may be deemed appropriate by the Board (collectively called the "**Investors**") up to an amount not exceeding Rs.50 crores including any premium and Green Shoe option attached thereto, inclusive of such premium as may be determined by the Board, at such time or times, at such price or prices in such manner and on such terms and conditions including fixing of record date or book closure and all other related or incidental matters as the Board may in its absolute discretion think fit including the discretion to determine the categories of investors to whom the offer, issue and allotment shall be made to the exclusion of the other categories of investors to whom the offer, issue and allotment considering the prevailing market conditions and other relevant factors and decide in consultation with the appropriate authority(ies), the merchant banker(s) and/or book runners) and for lead manager(s) and/or underwriters and/or advisor(s) and/or trustees) and/or such other person(s), but without requiring any further approval or consent from the share holders and also subject to the applicable regulations/guidelines for the time being in force.

RESOLVED FURTHER THAT pursuant to the provisions of Section 81(1A) and other applicable provisions if any of the Act the provisions of Chapter VIII of the SEBI ICDR Regulations and such other applicable provisions , the Board may at their absolute discretion, issue, offer and allot securities up to amount of Rs. 50 crores as specified above to qualified Institutional Buyers (as defined in the SEBI ICDR regulations)

pursuant to a qualified institutional placement, in accordance with the provisions of Chapter VIII of the SEBI ICDR Regulations and the relevant date for the determination of applicable price for the issue of securities means the date of the meeting in which the Board of the Company or the committee of Directors decided to open the proposed issue. Such securities shall be fully paid up and allotment of such securities shall be completed within 12 (twelve) months from the date of the share holders resolution approving the proposed issue or such other times as may be allowed by SEBI ICDR Regulation and such securities shall not be sold for a period of one year from the date of allotment, except on a recognized stock exchange, or except as may be permitted from time to time by the relevant SEBI ICDR Regulations.

RESOLVED FURTHER THAT in the event of issue of securities by way of Global Depository Shares (GDSs) and/or Global Depository Receipts (GDRs) and/or securities convertible into equity shares, and/or foreign Currency Convertible Bonds(FCCBs), the relevant date on the basis of which price of resultant shares shall be determined as specified under applicable law, shall be the date of the meeting in which the Board or the committee of Directors duly Authorised by the Board decides to open the proposal issue of securities.

RESOLVED FURTHER THAT for the purpose of giving effect of the above resolution and any other, issue and allotment of securities, the Board be and is hereby authorised to take all such action, give directions and to do all such acts, deed and things as may be necessary, desirable and incidental thereto and matters connected therewith including without limitation the entering into of arrangements including arrangements for the lead Managers, Underwriters, Registrars, Stabilizing Agent, Trustees, Bankers, Advisors and all such agencies as may be involved or concerned in such offerings of Securities and to remunerate them by way of commission, brokerage, fees or the like and also to enter into and execute all such arrangements, agreements, memoranda, documents etc. with such agencies and to seek the listing of such securities on one or more national and/or international stock exchange(s) and to do all requisite fillings with SEBI the Government of India, the RBI, if required and any other concerned authority in India or outside, and to do all such acts and things as may be necessary and expedient for, and incidental and ancillary to the issue and give such, directions that may be necessary or arise in regard to or in connection with any such offer, issue proceeds, as it may, in its absolute discretion, deem fit and any such action, decision or director of the Board shall be binding on all shareholders.

RESOLVED FURTHER THAT the Board and/or an agency or body authorised by the Board may issue or authorize the issue of Depositary Receipt(s)/Share Certificate(s)/ foreign currency convertible bonds and/or other forms of securities, representing the Securities issue by the Company, in registered or bearer form with such features and attributes as are prevalent in Indian and/or international capital markets for instruments of this nature and to provide for the tradability or free transferability thereof, as per the India/International practices and regulations and such other relevant regulatory authority as may be necessary and under the norms and practices prevalent in the India/International markets.

RESOLVED FURTHER THAT subject to the applicable laws, such of these Securities to be issued, as or not subscribed, may be disposed off by the Board to such persons and in such manner and on such terms as the Board as may in its absolute discretion think most beneficial to the Company, including offering or placing them with resident or non-resident /Foreign investor(s) (whether institutions and/or incorporated bodies and/or individuals and/or trusts and/or otherwise)/Foreign Institutional investors (FIIs)/Qualified institutional buyers (QIBs)/Foreign Corporate Bodies (FCBs)/Foreign Companies /Mutual Funds/Pension funds/Venture Capital Funds/banks and/or employees and business associates of the company or such other person(s) or entity(ies) or otherwise, to all or any of them jointly or severally, whether or not such investors are members of the Company, as the Board may in its absolute discretion decide.

RESOLVED FURTHER THAT the Board be and is hereby authorised to form a committee of Directors to give effect to the aforesaid resolutions and is authorised to take such steps and to do all such acts, deeds, matters and things and accept any alterations or modification(s) as they may be necessary to settle any question or difficulty that may arise in regard to issue and allotment of equity shares including but not limited to:

- (a) Approving the offer documents and filing the same with any other authority or persons as may be required;
- (b) Approving the issue price, the number of equity shares to be allotted, the basis of allocation and allotment of equity shares;
- (c) Arranging the delivery and execution of all contracts, agreements and all other documents, deeds, and instruments as may be required or desirable in connection with the issue of equity shares by the Company;

- (d) Opening a separate special account with a scheduled bank to receive monies in respect of issue of the equity shares of the Company;
- (e) Making applications for listing of the equity shares of the company on one or more stock exchange(s) and to execute and to deliver or arrange the delivery of the listing agreement(s) or equivalent documentation to the concerned stock exchange(s);
- (f) Finalization of the allotment of the securities on the basis of the bids received;
- (g) Finalization of and arrangement for the submission of the placement document(s) and any amendments supplements thereto, with any applicable government and regulatory authorities, institutions or bodies as may be required;
- (h) Approval of the preliminary and final placement document (including amending, varying or modifying the same, as may be considered desirable or expedient) as finalized in consultation with the Lead Manager/Underwriters/Advisors in accordance with all applicable laws, rules, regulations and guidelines;
- (i) Finalization of the basis of allotment in the event of over-subscription;
- (j) Acceptance and appropriation of the proceeds of the issue of the Securities;
- (k) Authorization of the maintenance of a register of holders of the Securities;
- (l) Authorization of any director or directors of the Company or other officer or officers of the Company, including by the grant of power of attorneys, to do such acts, deeds and things as authorized person in its absolute discretion may deem necessary or desirable in connection with the issue and allotment of the Securities;
- (m) Seeking, if required, the consent of the Company's lenders, parties with whom the Company has entered into various commercial and other agreements, all concerned government and regulatory authorities in India, and any other consents that may be required in connection with the issue and allotment of the Securities;
- (n) Seeking the listing of the Securities on any recognized stock exchange, submitting the listing application to such stock exchange and taking all actions that may be necessary in connection with obtaining such listing;

- (o) Giving or authorizing the giving by concerned persons of such declarations, affidavits, certificates, consents and authorities as may be required from time to time; and
- (p) Deciding the pricing and terms of the Securities, and all other related matters.

RESOLVED FURTHER THAT for the purpose of giving effect to the above resolutions, the Board be and is hereby authorized to agree to and make and accept such conditions, modifications and alterations stipulated by any of the relevant authorities while according approvals, consents or permissions to the issue as may be considered necessary, proper and expedient and to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary or desirable for such purpose, including without limitation the entering into of underwriting, marketing, depository, custodian and trustee arrangements and with power on behalf of the Company to settle any questions, difficulties or doubts that may arise in regard to any such issue(s)/offer(s) or allotment(s) or otherwise and utilization of the issue proceeds and/or otherwise to alter or modify the terms of issue, if any, as it may in its absolute discretion deem fit and proper without being required to seek any further consent or approval of the Company to the end and intent and the Company shall be deemed to have given its approval thereto expressly by the authority of this resolution.

RESOLVED FURTHER THAT the Board be and is hereby authorized to accept any modifications in the proposal as may be required by the authorities involved in such issues but subject to such conditions as the SEBI/GOI/RBI or such other appropriate authority, may impose at the time of their approval and as agreed to by the Board.

RESOLVED FURTHER THAT the Board be and is hereby authorised to delegate all or any of the powers herein conferred to any committee of Directors or Managing Director or any Director or any other officer or officers of the Company to give effect to the aforesaid resolutions.

RESOLVED FURTHER THAT the acts, deeds and thing already done by the Board or any designated officer of the Company in this regard be and are hereby confirmed, approved and ratified."

12. To consider and if thought fit, to pass with or without modification(s) the following resolution as a Special resolution.

AUTHORISATION TO GET SHARES LISTED WITH MADRAS STOCK EXCHANGE:

RESOLVED THAT pursuant to the provisions of the Companies Act, 1956, subject to the necessary permissions and approvals from Stock Exchanges and Securities and Exchange Board of India- SEBI, Registrar of Companies, AP and subject to other guidelines, necessary approvals from statutory and other necessary authorities, the Company be and hereby authorized to go for listing with Madras Stock Exchange.

RESOLVED FURTHER THAT Sri. Arvind Kumar Bhangadia, Managing Director and Arun Kumar Bhangadia, Chairman of the Company be and are hereby authorized jointly and severally to sign or execute the necessary documents, obtain necessary permissions/approvals from the statutory authorities, etc for the due compliance of the guidelines issued by SEBI/Stock Exchange from time to time to get the listing of the securities of the company with the stock Exchange – Madras.

By Order of the Board

Place : Hyderabad.
Dated : 30th July, 2010.

ARUN KUMAR BHANGADIA
Chairman

NOTES:

1. An explanatory statement pursuant to Section 173(2) of the Act is annexed herewith.
2. A member entitled to attend and vote is entitled to appoint a proxy to attend and vote instead of himself/herself and a proxy need not be a member of the company. The instrument of proxy in order to be effective shall be deposited at the registered office of the Company by not less than 48 hours before the commencement of the meeting.
3. The Register of Members and Share Transfer Books of the Company will remain closed from 25-08-2010 to 30-08-2010 (both days inclusive) for the purpose of Annual General Meeting and dividend.
4. Members / Proxies should bring the attendance slip duly filled in along with their Annual Report for attending the meeting.

By Order of the Board

Place: Hyderabad.
Dated: 30th July, 2010

ARUN KUMAR BHANGADIA
Chairman

ISO 9001:2008 Company

ANNEXURE TO THE NOTICE**INFORMATION PURSUANT TO CLAUSE 49 OF THE LISTING AGREEMENT
PROFILE OF DIRECTORS TO BE REAPPOINTED****MR. ARUN KUMAR BHANGADIA**

Sri Arun Kumar Bhangadia is a promoter director of the company. He is having vast experience of 25 years in the pharma industry and his services will immensely help the company in strengthening the business of the company. Hence the Board recommends his appointment for the approval of the members.

Number of Shares held - 1,33,12,000 Equity Shares of Rupee one each.

None of the Directors are interested in the above resolution except Sri. Arun Kumar Bhangadia and Sri. Arvind Kumar Bhangadia.

**EXPLANATORY STATEMENT PURSUANT TO SECTION 173 (2)
OF THE COMPANIES ACT, 1956****Item No. 5:**

Sri Arvind Kumar Bhangadia, Managing Director has been ever since his appointment being working for the development of the company and has made the significant contributions to the growth of the company. His remuneration was fixed 4 years back which as per recommendations of the remuneration committee was required to be revised. Change in Remuneration of Managing Director requires the approval of Shareholders. The Board recommends approval for the increased remuneration.

Number of Shares held by him in Company - 2,99,000 Equity Shares of Rupee one each.

None of the Directors are interested in the above resolution except Mr. Arun Kumar Bhangadia and Mr. Arvind Kumar Bhangadia.

ITEM NO. 6:

The equity share capital of the company is of face value of Rs.1/- each which now in the view of upcoming fund raising plans and listing at Madras Stock Exchange, the board proposes to consolidate into equity shares of Rs.10/- each (Rupees Ten Only). The proposed resolution is intended to give effect to the above proposal and hence is placed before the members for approval as a special resolution.

ITEM NO. 7 TO 9:

The present authorized capital of the Company is Rs. 7,00,00,000/- (Rupees Seven Crores only) divided into 7,00,00,000 equity shares of Rs.1/- each. It is proposed to increase the authorized share capital from existing Rs.7,00,00,000/- (Rupees Seven Crores Only) to Rs 20,00,00,000/- (Rupees Twenty Crores Only) by creation of additional 1,30,00,000/- equity shares of Rs.10/- each.

In accordance with the provisions of the Companies Act 1956, approval of members is required to enhance the authorised share capital and also for making the corresponding alterations to the capital clauses appearing in the Memorandum of Association and Articles of Association of the Company.

Your Directors recommend the resolutions set out at Item No 7 to 9 of the Notice for approval of members.

None of the Directors are concerned or interested in the said resolution.

ITEM NO. 10:

Your directors foresee a good business opportunities in the packing and power industry and are in the process of analyzing scope and feasibility of entering into the business activity and hence the board proposes to initially include the same in the Other objects of the company. And hence the resolution for amendment of objects of the company is placed before shareholders for approval.

ITEM NO. 11:

Your company is proposing to increase its share capital base by infusion of additional equity to fund the proposed expansion plans, augmentation of working capital, investment opportunities and other corporate purposes. Your company is proposing to create, offer issue and allot equity shares at such price, at discount or premium to market price or prices in such manner and on such terms as may be deemed appropriate by the board. The special resolution seeks to give the board powers to issue securities in one or more tranches, at such time and times. The detailed terms and conditions of the offer will be determined by the board in consultation with advisors, lead managers, underwriters and such other authorities as may be required and in accordance with the applicable provisions of law, and other relevant factors, empower the board.

The consent of the shareholders is being sought pursuant to the provisions of section 81 (1A) and other applicable provisions of companies Act, 1956 and in terms of the provisions of the listing agreement executed by the company with stock exchanges where equity shares of the company are listed. The special resolution if passed, will have effect of allowing the board to issue and allot shares to the investors who may or may not be the existing shareholders of the company.

None of the Directors of the company is, in any way, concerned or interested in the resolution. The board recommends the resolution for approval.

ITEM NO. 12:

In order to increase the marketability of the shares and facilitate the sale of shares by holders and more particularly those from Tamilnadu and Southern India, your company proposes to list the shares of the company in Madras Stock Exchange, Chennai.

None of the Directors of the company is, in any way, concerned or interested in the resolution. The board recommends the resolution for approval.

By Order of the Board

Place: Hyderabad.

Dated: 30th July, 2010

ARUN KUMAR BHANGADIA
Chairman

DIRECTORS' REPORT

To
The Members,

Your Directors have pleasure in presenting the 16th Annual Report on the business and operations of the Company together with the audited statements of accounts for the financial year ended 31st March, 2010.

FINANCIAL HIGHLIGHTS :

The Financial results for the year ended 31st March, 2010 are summarized as under:
(Rs. In Lakhs)

Particulars	2009-10	2008-2009
Income from operations	685.78	3160.66
Other Income	52.11	51.13
Total Expenditure	623.29	3141.50
Profit/Loss before Interest and Depreciation	114.60	70.28
Interest	0.05	1.16
Depreciation	23.70	22.79
Profit/Loss after Interest and Depreciation	90.85	46.33
Provision for Taxation		
- Current Tax	20.55	11.74
- Deferred Tax	01.31	02.83
- Fring Benifit Tax	NIL	00.36
- Previous Year's Tax Adjustment	NIL	(01.41)
Profit After Taxation	68.99	32.82
Appropriations		
- Proposed Dividend	20.25	20.25
- Provision for Tax on Dividend	3.36	03.44
- Transfer to General Reserve	6.90	03.28
Balance Brought Forward from Previous Year	35.52	29.67
Balance Carried to Balance Sheet	74.00	35.52
Earning Per Share	0.10	0.05

DIVIDEND:

Your board of directors has recommended a dividend of Re 0.03 Paisa (Three Paisa Only) (3%) per equity share which is subject to the approval of the Shareholders in the ensuing Annual general meeting of the Company. The total payment on account of dividend (Including Dividend Tax) shall be Rs.23.61 Lakhs.

REVIEW OF OPERATIONS:

The Company has earned a profit of Rs. 68.99 Lakhs after Tax. An amount of Rs 6.90 Lakhs has been transferred to General Reserve.

Financial Year 2009-10 is the better year for the Company. During the year under review, the turnover of the company was reduced due to scaling down the operation in stock market. However this reduction has no effect on the profitability of the company. The over all working of the company is satisfactory. The Company is looking at various cost reduction measures and hopes to improve the performance in the year to come. The Company also expects to enhance the shareholders value through a responsible strategy directed at building the brand value over a period of time.

DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to Section 217(2AA) of the Companies Act, 1956, the Directors confirm that:

- i) In the preparation of the Annual Accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures.
- ii) Appropriate accounting policies have been selected and applied consistently and have made judgement and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2010 and of the profit of the Company for the said period.
- iii) Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safe guarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- iv) The annual accounts have been prepared on a going concern basis.

AUDITORS:

The Statutory Auditors M/s. K. Venkateswara Rao & Associates, Chartered Accountants retire at the conclusion of the ensuing Annual General Meeting and being eligible, offer themselves for re-appointment.

DIRECTORS:

Mr. Arun Kumar Bhangadia, in accordance with provisions of the Companies Act, 1956 and the Articles of Association of the Company retire by rotation at the 16th Annual General Meeting and being eligible, offers himself for re-appointment. The board recommends his reappointment as a director of your company.

Brief profile of the directors seeking reappointment is given in Annexure to AGM Notice.

None of the Directors of the Company are disqualified under section 274 (1)(g) of the Companies Act, 1956.

FIXED DEPOSITS:

The Company has not accepted any fixed deposits U/s 58A and as such no amount of principle or interest was outstanding as on the date of Balance Sheet.

CONSERVATION OF ENERGY & TECHNOLOGY ABSORPTION:

The Company has no activity relating to conservation of energy or technology absorption. Further the company did not have any foreign exchange earnings or outgo during the year. Hence no information pursuant to section 217(1)(e) of the Companies Act, 1956 read with (disclosure of particulars in the report of Board of Directors) Rules, 1988 is provided.

LISTING OF SECURITIES:

The Equity Shares of your Company are traded at Bombay Stock Exchange Limited (BSE Indo Next Model) and listed at The Ahmedabad Stock Exchange Limited. The requisite Annual Listing Fees of the Ahmedabad Stock Exchange Limited had been paid as on the date of this report.

CORPORATE GOVERNANCE:

The Company's philosophy on Corporate Governance is attainment of the highest level of transparency, accountability and equity in all the spheres of operations, interactions with the shareholders, employees, government and others. And as per clause 49 of the Listing Agreement with the stock exchanges a separate section on Corporate Governance followed by the Company together with the certificate from the Auditors of the Company confirming Compliance is set out in the Annexure forming part of this Report.

CORPORATE SOCIAL RESPONSIBILITY:

Your Company recognized that its operations impact a wide community of stakeholders, including investors, employees, customers, business associates and local communities and that appropriate attention to the fulfillment of its corporate responsibilities can enhance overall performance. In structuring its approach to the various aspects of the corporate social responsibility, the company takes account of guide lines and statements issued by stake holder representatives and other regulatory bodies.

PARTICULARS OF EMPLOYEES:

None of the employees who is employed throughout the year are covered under section 217 (2A) of the Companies Act 1956 read with Companies (Particulars of Employees) Rules, 1975 as amended from time to time.

ACKNOWLEDGEMENT:

Your Directors place on record their appreciation for the valuable support extended by various departments viz., Commercial Tax department, Drug Control Department and Banks for their continued support to the Company's growth. The Directors record their special appreciation to all employees for their efforts and contribution towards the growth and achieving this performance.

Your Directors also wish to express their thanks to the shareholders for the confidence which they reposed in them.

For and on behalf of the Board

Place: Hyderabad.

Dated: 23rd July, 2010

ARUN KUMAR BHANGADIA

Chairman

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

The Company has earned a profit of Rs. 68.99 Lakhs after Tax. An amount of Rs 6.90 Lakhs has been transferred to General Reserve.

Industries structure and developments:

In India, Drugs and Pharmaceutical Industries are among the largest and the most advanced in the developing countries in terms of impact on the Societies they make. They Generate large employment pool and provide essential drugs to the vast and needy populations across the subcontinent and also across the globe. Indian Pharmaceutical Industry has made huge technological strides in the recent past and attained the know how of wide ranging capabilities in the complex domain of drug manufacturing.

Pharmaceutical Industry in India has been de-licensed and industrial licensing for most of the drugs and pharmaceutical products has been done away with.

Manufacturers are now free to produce any drug duly approved by the Drug Control Authority.

The Company Operations as on date are limited to Generic Drug Industry. A Generic Drug is identical to and bioequivalent of a branded drug in dosage form, safety, strength, route of administration, quality performance characteristics and intended use which US Food and Drug Administration (FDA) also confirms respective countries have intensive procedures for drug approval wherein various generic version also have to meet the stringent criteria in the same way as innovative drugs. The most important advantage with generic drug is that they are cheaper as no R&D investments are involved as in the case of new drugs. The prevailing fierce competition also makes the manufactures keep to low prices. Thus, generic drugs help various patients by making drug available at affordable prices while retaining the quality. In other words, generic drugs balance public interest especially in diseases like cancer and AIDS, the prevalence of which is very high, that too in developing countries and treatment with patented drugs is steeply priced.

Outlook:

Keeping in view of the current competitive marketing conditions and improving economic situations in the country, the company is looking at various cost reduction measures and hopes to perform better in its margins. The Company looks forward to greater reach and significant holding of hand with new business areas in the years to come. The Company also expects to enhance the shareholders value through a

responsible strategy directed at building value over the long-term.

Risk and concerns:

Risks and prospects are un-separable components of any company's business. The Directors and the Management of your Company keeping this in mind is taking all decisions so that no single shareholder is adversely affected on account of any decision taken by the Company. The Risk Management Committee of the company is working in this area, to assess the risks and minimize their incidence, so that the returns can be maximized.

Internal audit System:

During the year the Company had appointed M/s. Ramesh Athasniya & Company, Chartered Accountants as internal auditors to the Company an external audit firm of Chartered Accountants, who submits reports on quarterly basis. The reports are placed before the Audit Committee and comments and suggestions made by the internal auditors are noted and implemented by the Company.

Cautionary Statement:

Statements in this Management Discussion and Analysis Report may be "forward looking statements" within the meaning of applicable securities laws and regulations. These statements are based on certain assumptions and expectations of future events. Actual results could differ materially from those expressed or implied. Important facts that could make a difference at the Company's operations include economic conditions affecting domestic demand and supply conditions, finished goods prices, changes in government regulations and tax regime etc. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of subsequent developments, information or events.

CORPORATE GOVERNANCE REPORT

COMPANIES PHILOSOPHY ON THE CODE OF CORPORATE GOVERNANCE

The Company always strives to achieve optimum performance at all levels by adhering to corporate governance practices and envisages fair and transparent business practices, effective management control by the Board, adequate representation of promoter, executive and independent directors on the Board, accountability for performance, monitoring of executive performance by the Board, compliance of laws, transparent and timely disclosure of financial and management information and voluntary best practices and disclosures.

BOARD OF DIRECTORS:

a) Composition

Category	Number of Directors	Non-Executive	Executive
Promoter Directors	2	1	1
Independent Directors	3	3	Nil

b) Board Meetings

The Board of Directors of the Company shall meet at least four times a year, with a time gap of not more than four months between any two meetings.

During the year the meeting(s) of the Board of Directors held 6 times viz. as per the below table.

Particulars	Date
First Meeting	28.04.2009
Second Meeting	18.06.2009
Third Meeting	25.07.2009
Fourth Meeting	28.08.2009
Fifth Meeting	25.10.2009
Sixth Meeting	31.01.2010

Agenda papers along with necessary statements were circulated to the Directors in advance for each of those meetings and all the relevant information was placed before the Board from time to time.

c) Attendance of each Director at the Board Meeting during the year and at Last Annual General Meeting including other Directorships.

Name of Director	Attendance		No. of other Directorships	Committee Membership
	Board Meetings	Last AGM		
Mr. Arvind Kumar Bhangadia	6	Y	2	1
Mr. Murlidhar Mutgi	6	Y	Nil	3
Mr. Ramswaroop Agarwal	6	Y	1	3
Mr. Arun Kumar Bhangadia	6	Y	4	2
Mr. Arun Kumar Sarda	3	Y	1	2

Audit Committee:

The Audit committee consists of the following directors:

Mr. Ramswaroop Agarwal	- Chairman	- Independent Non-Executive Director
Mr. Murlidhar Mutgi	- Member	- Independent Non-Executive Director
Mr. Arun Kumar Bhangadia	- Member	- Promoter Non-Executive Director

During the year under review, four Audit Committee meetings were held on 24th April, 2009, 22nd July 2009, 20th September, 2009, 28th January 2010

The scope of the committee includes: -

a) Reviewing with the management the periodic financial statements before submission to the board, focusing primarily on:

- Any changes in accounting policies and practices.
- The going concern assumption.
- Qualifications in draft audit report.
- Major accounting entries based on exercise of judgment by the Management.
- Significant adjustments arising out of audit.
- Compliance with accounting standards.
- Compliance with Stock Exchange and legal requirements concerning financial statements.
- Any related party transactions i.e. transactions of the Company of material nature, with promoters, or the management, their subsidiaries or relatives etc. that may have a potential conflict with the interest of the Company at large.

- b) Reviewing with the management, statutory and internal auditors, and the adequacy of internal control system and recommending improvements to the management.
- c) Reviewing the adequacy of the internal audit function, discussion with the internal auditors about any significant findings and follow up thereon.
- d) Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.
- e) Reviewing financial and risk management policies of the Company.
- f) Such other matters as may be entrusted to the committee from time to time.

REMUNERATION COMMITTEE :

The remuneration committee consists of the following Directors:

Mr. Murlidhar Mutgi	- Chairman	- Independent Non-Executive Director
Mr. Ramswaroop Agarwal	- Member	- Independent Non-Executive Director
Mr. Arun Kumar Bhangadia	- Member	- Promoter Non-Executive Director
Mr. Arun Kumar Sarda	- Member	- Independent Non-Executive Director

The Remuneration committee meeting was held on 15th day of July, 2009 during the year under review.

The details of the remuneration to the managerial personnel of the company for the financial year 2009-2010 are as under.

The Company had paid an amount of Rs.2,40,000 to Mr. Arvind Kumar Bhangadia, Managing Director of the Company as Salary to the Director.

INVESTOR'S GRIEVANCE COMMITTEE:

The investor's grievance committee consists of the following directors.

Mr. Arvind Kumar Bhangadia	- Chairman	- Promoter Non-Executive Director
Mr. Murlidhar Mutgi	- Member	- Independent Non-Executive Director
Mr. Ramswaroop Agarwal	- Member	- Independent Non-Executive Director
Mr. Arun Kumar Sarda	- Member	- Independent Non-Executive Director

The Investors' Grievance Committee of the Board is empowered to oversee the redressal of investor's complaints pertaining to share transfers, non-receipt of annual reports, issue of duplicate certificates, transmission (with and without legal representation) of shares. Its scope also includes delegation of powers to the executives of the Company share transfer agents to process share transfers and other investor-allied matters.

The Committee meets periodically to take care of the issues relating to share transfers and other shareholder's correspondence or grievances.

During the year under review no complaint is pending as on date of this report.

GENERAL BODY MEETINGS:

Location and time of General Meetings for the last three years :

Year	Type	Date	Venue	Time
2008-2009	AGM	07.09.2009	RGA Hall, Snatak Bhavan, 5-4-790/1, Ashirvad Complex, 1st Floor, Abids, Hyderabad – 500 001.	4.30 P.M.
2007-2008	AGM	29.09.2008	RGA Hall, Snatak Bhavan, 5-4-790/1, Ashirvad Complex, 1st Floor, Abids, Hyderabad – 500 001.	10.30 A.M.
2006-2007	AGM	28.09.2007	RGA Hall, Snatak Bhavan, 5-4-790/1, Ashirvad Complex, 1st Floor, Abids, Hyderabad – 500 001.	11.30 A.M.

RELATED PARTY TRANSACTIONS:

During the year the Company has dealt with the following persons, where such persons are Directors/Directors' Relatives.

Name of the Person	Relationship	Amount (Rs.)	Nature of Transaction
Arvind Kumar Bhangadia	Managing Director	2,40,000	Salary Paid
Arun Kumar Bhangadia	Chairman	3,00,000	Rent Paid
Jyothi Bhangadia	Director's Relative	84,000	Rent Paid
Kiran Bhangadia	Director's Relative	3,00,000	Rent Paid
TDPL Health Care (India) Ltd.	Company in Which Mr. Arun Kumar Bhangadia and Mr. Arvind Kumar Bhangadia, are Directors.	25,82,300	Sale of Investments
TDPL Health Care (India) Ltd.	Company in Which Mr. Arun Kumar Bhangadia and Mr. Arvind Kumar Bhangadia, are Directors.	2,00,05,764	Medicines purchased from TDPL Health Care (India) Ltd.

- i) The Management of the Company feels that the Rent paid to above Directors and their relatives was reasonable when compared to prevailing market prices in the similar areas.
- ii) The Medicines Purchased from TDPL Health care (India) Ltd: M/s. TDPL Health Care (India) Ltd: is C&F Agent and the Price paid for such medicines is reasonable when compared to prevailing market prices in the similar areas.

MEANS OF COMMUNICATION:

The Company has published its financial results on a quarterly and half yearly basis as well as Annual results in English and Telugu newspapers and the same has been submitted to the Stock Exchanges.

FINANCIAL CALENDAR 2010-2011 (TENTATIVE SCHEDULE) :

Financial reporting for the quarter ending June 2010	23 rd July 2010
Financial reporting for the quarter ending September 2010	By the end of October 2010
Financial reporting for the quarter ending December 2010	By the end of January 2011
Financial reporting for the quarter ending March 2011	By the end of April 2011

GENERAL SHAREHOLDER INFORMATION:

- a) Annual General Meeting : 30th August, 2010
- b) Financial Year : 1st April to 31st March
- c) Book Closure Date : 25th August, 2010 to 30th August, 2010
(both days inclusive)

LISTING:

Presently, the Company's securities are traded on Bombay Stock Exchange Limited (BSE Indo Next Model) & listed at The Ahmedabad Stock Exchange Ltd (ASE).

MARKET INFORMATION:

The Performance of the stock in Bombay Stock Exchange Limited for the period from 1st April, 2009 to 31st March, 2010 was as follows.

Month	Bombay Stock Exchange Limited (BSE)		
	High	Low	Volume
April - 2009	17.00	11.00	21656
May - 2009	18.90	11.11	86659
June - 2009	39.35	18.00	1288507
July - 2009	32.00	23.65	824850
August - 2009	34.40	27.60	827328
September - 2009	51.50	32.00	1716081
October - 2009 ##	52.90	5.05	4702494
November - 2009	5.79	4.91	2996580
December - 2009	6.72	5.40	3420556
January - 2010	7.46	4.98	6232171
February - 2010	7.18	4.39	2701876
March - 2010	5.70	4.50	983256

Stock Split from Rs 10/- to Re.1/- during the year in October 2009.

DEMATERIALIZATION OF SHARES:

Particulars	No.of Shares	% of Total Issued Capital
Issued Capital	6,75,00,000	100.00
Held in Dematerialised form in CDSL	5,46,16,305	80.91
Held in Dematerialised form in NSDL	53,46,488	7.92
Held in Physical	75,37,207	11.17
Total No.of Shares	6,75,00,000	100.00

The ISIN is Active in NSDL and CDSL and ISIN No is **INE314I01028**

SHARE TRANSFER SYSTEM :

All the share transfers are processed at the registrars and share transfer agents of the company M/s. Venture Capital Corporate & Investments Pvt. Ltd., and approved by the Share Transfer Committee of the Company.

REGISTRAR AND TRANSFER AGENTS:

Members are requested to correspond with the Company's Registrar and Share Transfer Agents for transfer, delivery or any other correspondence

Venture Capital & Corporate Investments Private Limited

12-10-167, Bharat Nagar, Hyderabad - 500 018 Andhra Pradesh.

E-mail: info@vccilindia.com Tel No. (040) 23818475/23818476

DISTRIBUTION OF SHARE HOLDING AS ON 31.03.2010

Range of Ordinary Shares	No of Holders	% to Holders	No of Shares	% of Capital
Up to 500	273	9.40	52,226	0.07
501 to 1000	703	24.21	6,96,304	1.03
1001 to 2000	1,125	38.75	22,34,934	3.31
2001 to 3000	294	10.12	8,77,404	1.30
3001 to 4000	52	1.79	2,05,376	0.30
4001 to 5000	115	3.96	5,69,664	0.84
5001 to 10000	139	4.78	11,48,332	1.70
10000 above	202	6.95	6,17,15,760	91.43
Total	2903	100	6,75,00,000	100

SHARE HOLDING PATTERN AS ON 31.03.2010

Category	As on 31 st March, 2010	
	No of Shares	Percentage of Shareholding (%)
Promoter's Holding		
Promoters		
- Indian Promoters	47,33,8000	70.13
Persons acting in concert	-----	-----
Sub-total:	47,33,8000	70.13
Non-Promoters Holding		
Private Corporate Bodies	42,93,042	06.36
Indian Public	15,86,8958	23.51
Sub-total:	20,16,2000	29.87
GRAND TOTAL	6,75,00,000	100.00

CERTIFICATE

- a. We have reviewed the financial statements and the cash flow statement for the year and that to the best of our knowledge and belief :
 - i. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
 - ii. These statements together present a true and fair view of the Company's affairs and are in compliance with the existing accounting standards, applicable laws and regulations.
- b. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal, violate the Company's code of conduct.
- c. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of the internal control systems of the Company pertaining to financial reporting and we have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

- d. We have indicated to the Auditors and the Audit Committee
 - i. Significant changes in internal controls over financial reporting during the year.
 - ii. Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements ; and
 - iii. Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For **Trimurthi Drugs & Pharmaceuticals Ltd.,**

SD/-
Arvind Kumar Bhangadia
Managing Director

Place: Hyderabad.
Date : 23 July 2010

SD/-
Arun Kumar Bhangadia
Chairman

DECLARATION ON COMPLIANCE WITH CODE OF CONDUCT

Compliance of Code of Conduct for Directors and Senior Management Personnel pursuant to the amended provisions of Clause 49 of the Listing Agreement.

The Board laid down a Code of Conduct for all Board Members and Senior Management Personnel of the Company.

All the Board Members and Senior Management Personnel affirmed that they have complied with the said Code of Conduct on an annual basis in respect of the financial year ended 31.03.2010

SD/-
Arvind Kumar Bhangadia
Managing Director

Place: Hyderabad.
Date : 23rd July 2010

SD/-
Arun Kumar Bhangadia
Chairman

**Auditor's Certificate on Compliance with Conditions of Corporate Governance
Under Clause 49 of the Listing Agreement**

To
The Members of
M/s. Trimurthi Drugs & Pharmaceuticals Ltd.,

We have examined the Compliance with conditions of Corporate Governance of M/s. Trimurthi Drugs & Pharmaceuticals Ltd., for the year ended 31st March, 2010 as stipulated in clause 49 of the Listing Agreement with Stock Exchanges.

The Compliance with the conditions of Corporate Governance is the responsibility of the Management. Our examination has been limited to review the procedures and implementations thereof adopted by the Company for ensuing the compliance with the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statement of the Company.

In our opinion and to the best of our information and according to the explanations given to us and representations made by the Directors and the Management's, we certify that the company has compiled with conditions of the Corporate Governance as stipulated in Clause 49 of the above mentioned Listing agreement.

As required by the guidance note issued by the Institute of Chartered Accountants of India, we have to state that no grievances of investors are pending for a period exceeding one month against the Company as per the records maintained by the Company.

We further state that such compliance is neither an assurance as to future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the company.

**For K. Venkateswara Rao & Associates
Chartered Accountants**

SD/-
(K.Venkateswara Rao)
Proprietor.

Place: Hyderabad.
Date: 23rd July 2010

AUDITOR'S REPORT

To

The Members of

M/s TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

1. I have audited the attached balance sheet of M/s TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED as at 31st March, 2010, and the Profit & Loss A/c for the year ended on that date annexed thereto. These financial statements are the responsibility of the Company's management. My responsibility is to express an opinion on these financial statements based on my audit.
2. I conducted my audit in accordance with the accounting standards generally accepted in India. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. I believe that my audit provides a reasonable basis for my opinion.
3. As required by the Companies (Auditor's Report) Order, 2003 issued by the Central Government of India in terms of Sub-section(4A) of section 227 of the Companies Act, 1956, we enclose in the Annexure a statement on the matters specified in paragraphs 4 and 5 of the said order.
4. Further to my comments in the Annexure referred to above, I report that:
 - (i) I have obtained all the information and explanations, which to the best of my knowledge and belief were necessary for the purposes of my audit;
 - (ii) In my opinion, proper books of accounts as required by law have been kept by the company so far as appears from our examination of those books.
 - (iii) The balance sheet and the profit and loss account dealt with by this report are in agreement with the books of account.

- (iv) In my opinion, the balance sheet and the profit and loss account dealt with by this report comply with the accounting standards referred to in sub-section (3C) of section 211 of the Companies Act, 1956.
- (v) On the basis of written representations received from the directors, as on 31st March, 2010 and taken on record by the Board of Directors, we report that none of the directors is disqualified as on 31st March, 2010 from being appointed as a director in terms of clause(g) of sub-section(1) of section 274 of the Companies Act, 1956.
- (vi) In my opinion and to the best of our information and according to the explanations given to me, the said accounts give the information required by the Companies Act, 1956, in the manner so required and give true and fair view in conformity with the accounting principles generally accepted in India:
 - (a) In the case of the balance sheet, of the state of affairs of the company as at 31st March, 2010.
 - (b) In the case of the profit and loss account, of the Profit for the year ended on that date.

For **K.VENKATESWARA RAO & ASSOCIATES**
CHARTERED ACCOUNTANTS

PLACE : HYDERABAD

DATE : 23rd July 2010

K.VENKATESWARA RAO

PROPRIETOR

M.NO.027305

FRN 006374S

ANNEXURE

Referred to in paragraph 3 of my report of even date,

- (i) (a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.
- (b) All the assets have been physically verified by the management during the year and in my opinion, the frequency of verification is reasonable having regard to the size of the company and nature of its assets. No material discrepancies were noticed on such verification.
- (c) During the year, the company has not disposed off any major part of the plant and machinery.
- (ii) (a) The inventory has been physically verified during the year by the management. In my opinion, the frequency of verification is reasonable.
- (b) The procedures of physical verification of inventories followed by the management are reasonable and adequate in relation to size of the company and nature of the business.
- (c) The company is maintaining proper records of inventory. The discrepancies noticed on verification between physical stock and book records were not material.
- (iii) (a) The company had not taken any loans from the companies covered in the register maintained under section 301 of the Companies Act, 1956.
- (b) In my opinion, the rate of interest and other terms and conditions on which loans have been granted to companies listed in the register maintained under section 301 of the Companies Act, 1956 are not *prima facie*, prejudicial to the interest of the company.
- (c) The parties to whom loans have been given, have repaid the principle amounts as stipulated and have been regular in the payment of interest.
- (d) There is no overdue amount of loans granted to companies listed in the register maintained under section 301 of the Companies Act, 1956.
- (iv) In my opinion and according to the information and explanations given to me, there are adequate internal control procedures commensurate with the size of the company and the nature of its business with regard to purchases of inventory, fixed assets and with regard to the sale of goods. During the course of my audit, I have not observed any continuing failure to correct major weakness in internal controls.

- (v) (a) According to the information and explanations given to me, we are of the opinion of that transactions that need to be entered into the register maintained under Section 301 of the Companies Act, 1956 have been so entered.
- (b) In my opinion and according to the information and explanations given to me, the transactions made in pursuance of contracts of arrangements entered in the register maintained under section 301 of the Companies Act, 1956 and exceeding the values of rupees five lakhs in respect of any party during the year have been made at prices which are reasonable having regard to prevailing market prices at the relevant time.
- (vi) In my opinion and according to the information and explanations given to me, the company has not accepted any deposits from the public during the year under reference.
- (vii) In my opinion, the company has an adequate internal audit system commensurate with the size and nature of its business.
- (viii) As per the information given to me, the Central government has not prescribed maintenance of Cost records under Section 209(1) (d) of the Companies Act, 1956.
- (ix) (a) The company is regular in depositing with appropriate authorities undisputed statutory dues. As explained to me the company has not established any Provident Fund Scheme to its employees, as the provisions of the Provident Fund Act and Employees State Insurance Act are not applicable to this company.
- (b) According to the information and explanations given to me, no undisputed amounts payable in respect of income tax, wealth tax, sales tax, customs duty, excise duty and cess were in arrears, as at 31st March, 2010 for a period of more than six months from the date they became payable.
- (c) According to the information and explanations given to me, there are no dues of income tax, sales tax, wealth tax, excise duty and cess, which have not been deposited on account of any dispute.
- (x) The company is not having any accumulated losses. The company has not incurred cash losses during the financial year covered by our audit and also for the immediately preceding financial year.
- (xi) In my opinion and according to the information and explanations given to me, the company has not defaulted in repayment of dues to bank.

- (xii) In my opinion the company has not granted any loans and advances on the basis of security by way of pledge of shares, debentures and other securities.
- (xiii) In my opinion, the company is not a chit fund or a nidhi mutual benefit fund/society. Therefore, the provisions of clause 4(xiii) of the Companies (Auditor;s Report) Order, 2003 are not applicable to the Company.
- (xiv) In my opinion, the company is dealing in and trading in shares, securities, debentures and other investments and accordingly, the company has maintained adequate records to show full particulars of the transactions and contracts entered into in respect of dealing and trading in shares, securities and other investments and the timely entries have been made in such records.
- (xv) In my opinion and according to the explanations given to me, the company has not given any guarantees for loans taken by others from banks or financial institutions.
- (xvi) In my opinion, the company has not availed any term loans.
- (xvii) According to the information and explanations given to us and on an overall examination of the balance sheet of the company, we report that the funds raised on short-term basis have not been used for long term investment. And no long term funds have been raised by the company.
- (xviii) According to the information and explanations given to me, the company has not made any preferential allotment of shares to parties and companies covered in the register maintained under section 301 of the Act.
- (xix) According to the information and explanations given to me, during the period covered by my audit report, the company has not issued any debentures.
- (xx) The company, during the year has not raised money by public issues.
- (xxi) According to the information and explanations given to me, no fraud on or by the company has been noticed or reported during the courses of my audit.

For **K.VENKATESWARA RAO & ASSOCIATES**
CHARTERED ACCOUNTANTS

PLACE : HYDERABAD
DATE : 23rd July 2010

(K.VENKATESWARA RAO)
(PROPRIETOR)

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
BALANCE SHEET AS on 31st March, 2010

Particulars	Schedule Number	As on 31.03.2010		As on 31.03.2009
SOURCES OF FUNDS				
A. SHARE HOLDERS FUNDS				
a) Share Capital	1	67,500,000		67,500,000
b) Reserves & Surplus	2	8,747,253		4,209,737
			76,247,253	
B. SECURED LOANS	3		2,256,077	71,709,737
C. DEFERRED TAX LIABILITY			2,056,118	2,014,039
			80,559,448	1,925,627
				75,649,403
APPLICATION OF FUNDS				
A. FIXED ASSETS :	4			
Gross Block		27,928,102		24,762,777
Less : Accumulated Depreciation		9,713,229		7,343,161
			18,214,873	
B. INVESTMENTS	5		8,054,000	17,419,616
C. CURRENT ASSETS, LOANS & ADVANCES:				2,499,000
a) Cash & Bank Balances	6 (a)	1,699,492		9,720,650
b) Deposits	6 (b)	2,001,549		3,092,549
c) Closing Stock	6 (c)	8,019,809		5,534,449
d) Sundry Debtors	6 (d)	11,250,624		9,398,937
e) Loans & Advances	6 (e)	37,614,770		34,876,048
			60,586,244	
Less: Current Liabilities & Provision				
a) Current Liabilities	7 (a)	1,879,005		3,312,479
b) Provision for Expenses	7 (b)	4,416,663		3,579,367
			6,295,668	
Net Current Assets			54,290,576	6,891,846
TOTAL			80,559,448	55,730,788
Notes to Accounts	11			75,649,403

As per our report of even date,
For K.Venkateswara Rao & Associates,
Chartered Accountants,

For and on behalf of the Board

Arvind Kumar Bhangadia
Managing Director

C.A.K.Venkateswara Rao,
Proprietor.
M.No. 027305

Place : Hyderabad
Date : 22nd July 2010

Arun Kumar Bhangadia
Chairman

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31st March, 2010

Particulars	Schedule Number	As on 31.03.2010	As on 31.03.2009
A. INCOME:			
Sales		40,986,361	42,354,528
Sale of Shares		27,591,623	273,711,018
Profit on Sale of Investment		95,487	391,350
Interest, Dividend and Other Income	8	5115848	4342798
Closing Stock	6 (c)	8,019,809	5,534,449
TOTAL (A)		81,809,128	326334143
B. EXPENDITURE:			
Opening Stock		5,534,449	11,570,762
Purchases		35,607,412	29407882
Purchases of Shares		24,085,244	272,169,724
Loss on Assets		NIL	2,584
Administration & Other Expenses	9	4,385,607	4,711,499
Selling & Distribution Expenses	10	7,41,678	1,559,492
Depreciation		2,370,068	2,279,201
TOTAL (B)		72,724,458	321701143
C. Net Profit Before Prior Adjustment		9,084,670	4,633,000
D. Adj. relating to Taxes of Previous Years :			
TDS Unclaimed Written off		NIL	9,256
Income Tax/MAT		NIL	(150633)
E. Net Profit Before Tax :		9,084,670	(141,377)
F. Provision For Taxation :			4,774,377
Provision for Taxation / MAT (including Interest)		2,055,331	1,174,225
Deferred Tax		1,30,491	2,82,413
Fringe Benefit Tax		NIL	35,892
G. Profit After Tax (Before appropriations)		2,185,822	1,492,530
H. Proposed Dividend		6,898,848	3,281,847
Add. : Dividend Distribution Tax		2,025,000	2,025,000
Amount Transferred to General Reserve		3,36,332	3,44,250
		2,361,332	2,369,250
		6,898,85	3,28,185
I. Net Profit After Appropriations		3,051,217	2,697,435
J. Add/(Less) : Previous Year Balance		3,847,631	584,412
K. Balance Carried to Balance Sheet		3,551,837	2,967,425
L. Earning Per Share		7,399,468	3,551,837
Basic		0.10	0.05
Diluted		0.10	0.05
Notes of Accounts	11		

As per our report of even date,
For K.Venkateswara Rao & Associates,
Chartered Accountants,

For and on behalf of the Board

**C.A. K.Venkateswara Rao,
Proprietor.
M.No. 027305**

Arvind Kumar Bhangadia
Managing Director

Place : Hyderabad
Date : 22nd July 2010

Arun Kumar Bhangadia
Chairman

39 16th Annual Report 2009-2010

ISO 9001:2008 Company

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
SCHEDULES ANNEXED TO AND FORMING PART OF BALANCE SHEET

Particulars	As at 31.03.2010 (Rs.)	As at 31.03.2009 (Rs.)
SCHEDULE -1 SHARE CAPITAL Authorised Capital 70,000,000 Equity Shares of Re 1/- each Previous Year : 7,000,000 Equity Shares of Rs.10/- each	70,000,000	70,000,000
Issued, Subscribed and Paid-up Capital 67,500,000 Equity Shares of Re 1/- each fully Paid Previous Year :6,750,000 Equity Shares of Rs.10/- each fully paid	67,500,000	67,500,000
SCHEDULE -2 RESERVES & SURPLUS (A) General Reserve Opening Balance Add. : Transfer during the year	6,57,899 6,89,885 1,347,784	329714 328185 657899
(B) Profit & Loss Account : Opening Balance Add. : Current Year Profit	3,551,838 3,847,631 7,399,469 8,747,253	2967426 584412 3551838 4209737
SCHEDULE -3 Secured Loans ING Vyasya Bank OD (Secured by Lien of Fixed Deposit Receipt) ICICI Bank Car Loan	NIL 2,256,077 2,256,077	2014039 NIL 2,014,039
SCHEDULE -5 Investments Unquoted Lotus Properties & Developers India Ltd., (83,300 Shares) (Valued at Cost) Quoted Property at Gandhi Nagar, Hyderabad Flats at Khajaguda, Hyderabad	NIL 30,000,00 5,054,000 8,054,000	2,499,000 NIL NIL 2,499,000

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

SCHEDULE-4

STATEMENT OF FIXED ASSETS & DEPRECIATION

Particulars	Rate	Gross Block			Depreciation				Net Block	
		Cost as at 01-04-2009	Additions/ (Deletions)	Total upto 31-03-2010	Upto 01-04-2009	For the Year	Adj.	Total	As at 31-03-2010	As at 31-03-2009
Building & Civil Works	1.63%	625,616	90237	715853	28	11052	NIL	11080	704773	625588
Furniture & Fittings	6.33%	414899	72619	487518	222854	28933	NIL	251787	235731	192045
Mobile	6.33%	55,530	19000	74530	14428	4372	NIL	18800	55730	41102
Vehicles	9.50%	2714397	2726549	5440946	545905	206121	NIL	752026	4688920	2168492
Computers	16.21%	419056	70673	489729	342790	76246	NIL	419036	70693	76266
Air Conditioner	6.33%	233850	NIL	233,850	81512	14803	NIL	96315	137535	152338
Office Equipments	6.33%	274129	40122	314251	120039	19370	NIL	139409	174842	154090
Camera	6.33%	NIL	65390	65390	NIL	1055	NIL	1055	64335	NIL
Television	0.00%	10,600	NIL	10,600	10,500	NIL	NIL	10,500	100	100
Printer	16.21%	14700	18050	32750	5105	4517	NIL	9622	23128	9595
Telephone Instruments	100%	NIL	2935	2935	NIL	2835	NIL	2835	100	NIL
Intangible Assets :										
Intangible Assets	NIL	20000000	NIL	20000000	6000000	2000000	NIL	8000000	12000000	14000000
Website	33.33%	NIL	59750	59750	NIL	764	NIL	764	58986	NIL
TOTAL		24762777	3165325	27928102	7343161	2370068	NIL	9713229	18214873	17419616

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
SCHEDULES ANNEXED TO AND FORMING PART OF BALANCE SHEET

Particulars	As on 31.03.2010 (Rs.)	As on 31.03.2009 (Rs.)
SCHEDULE - 6 CURRENT ASSETS, LOANS AND ADVANCES		
A) Cash & Bank Balances :		
i. Cash on Hand	175571	343015
ii. Bank Balances with Scheduled Banks in :		
a) Current Accounts	877635	
b) Fixed Deposit Accounts	8500000	
	1208237	9377635
	315684	9720650
	1523921	
	1699492	
	1,549	1549
	2000000	3091000
	2001549	3092549
	8019809	5534449
	NIL	NIL
	8019809	5534449
B) Deposits :		
i. With Government/Quasi Govt Authorities		
ii. With Others		
	1,549	1549
	2000000	3091000
	2001549	3092549
C) Closing Stock :		
i. Closing Stock of Pharmaceuticals		
ii. Closing Stock of Shares		
	8019809	5534449
	NIL	NIL
	8019809	5534449
D) Sundry Debtors:		
i. Debtors outstanding for a period exceeding 6 months		
Considered Good	NIL	
Considered Doubtful	814198	1154198
	814198	1154198
	11250624	9398937
	12064822	10553135
	814198	1154198
	11250624	9398937
	33496958	28568464
	3120124	5295799
	997688	1011785
	37614770	34876048
E) Loans & Advances:		
i. Loans		
ii. Advances recoverable in Cash or in kind or for value to be received		
iii. Advance Tax & TDS		

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
SCHEDULES ANNEXED TO AND FORMING PART OF BALANCE SHEET

PARTICULARS	As on 31.03.2010 (Rs.)	As on 31.03.2009 (Rs.)
SCHEDULE -7 Current Liabilities & Provisions		
A) CURRENT LIABILITIES :		
Sundry Creditors		
Dues Other than SSI Units	862485	2849618
Dues to SSI Units	NIL	152067
Other Creditors	25229	NIL
Trade Deposits	230000	110000
Outstanding Expenses	210257	189857
TDS Payable	16422	10937
ING Vysya Bank Current Account	534612	NIL
	1879005	3312479
B) Provisions :		
FBT Payable	NIL	35892
Income Tax Payable	2055331	1174225
Provision for Proposed Dividend	2025000	2025000
Provision for Dividend Distribution Tax	336332	344250
	4416663	3579367
SCHEDULE-8		
Interest, Dividend & Other Income :		
Interest	4258037	4257521
Dividend	116263	7317
Interest on IT Refund	NIL	39260
Other Income / Chit Dividend / Commission	541548	38700
Provision for Bad Debts Written Off	200000	NIL
	5115848	4342798

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

PARTICULARS	As on 31.03.2010 (Rs.)	As on 31.03.2009 (Rs.)
SCHEDULE -9		
Administrative Expenditure		
Advertisement Expenses	43652	62935
Annual Custodial Fee	48477	24132
Audit Fees	88240	40000
Bank Charges	42609	37024
Boarding & Lodging Expenses	51865	40342
Donations	16100	NIL
Directors Remuneration	240000	240000
Electricity Chargers	37044	28524
General Expenses	116093	59900
Insurance Charges	47393	58887
Interest Paid	5489	115963
Listing Fee	11030	11236
License & Fees	43545	3164
Postage & Telegrams	37357	16812
Printing & Stationary	150189	193526
Provision for Doubtful Debts	NIL	814198
Professional Charges	278979	218646
Rates & Taxes	33546	42099
Rent	684000	684,000
Repairs & Maintenance	255488	152638
Salaries	1970078	1751431
Subscriptions & Periodicals	8370	3510
Telephone & Internet Expenses	59917	79845
Travelling Expenses	116145	30887
Website Domain Charges	NIL	1800
	4385607	4711499
SCHEDULE-10		
Selling & Distribution		
Commission on Sale	219386	279166
Rate Difference	NIL	132794
Discount	190795	296525
Carriage Outward Expenses	304558	321015
Other Selling Expenses	26939	529992
	741678	1559492

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**SCHEDULE – 11****SIGNIFICANT ACCOUNTING POLICIES & NOTES ON ACCOUNTS****A. SIGNIFICANT ACCOUNTING POLICIES:****1. Basis of Preparation of Financial Statements:**

- (i) Financial Statements have been prepared under the historical cost convention, in accordance with the generally accepted accounting principles and provisions of the Companies Act, 1956 as applicable to this Company.
- (ii) Accounting Policies not specifically referred to otherwise are consistent and in consonance with the generally accepted accounting principles followed by the Company.

2. Basis of Accounting:

All Income and Expenditure items are recognised on accrual basis. However, Dividend Income is accounted for on Receipt Basis.

3. Fixed Assets & Depreciation:

- (i) Fixed Assets are valued at cost less Depreciation. Cost includes all expenses incurred for acquisition of assets and the expenditure incurred for renovation on leased premises has been Capitalised.
- (ii) The Company provides Depreciation on Straight Line Method at the rates and in the manner specified under Schedule XIV of the Companies Act, 1956. For the Intangible assets the depreciation has been provided by considering the useful life of the assets as 10 years. For the Intangible Assets added during the year namely Website

Development, the useful life is estimated as Three years and accordingly depreciation has been provided on prorata basis.

4. Inventories:

Closing Stock had been valued at Cost or Market Value whichever is lower.

5. Retirement Benefits:

Employees post retirement benefits such as Gratuity, Pension and leave Encashment will be accounted as and when it arises.

6. Impairment of Assets:

No asset was identified as impaired during the year.

7. Cash Flow Statement:

The Cash Flow Statement is prepared by the “Indirect Method” set out in Accounting Standard (AS) – 3 on “Cash Flow Statements” and presents the cash flows by operating, investing and financing activities of the company. Cash and Cash equivalents presented in the Cash Flow Statement consist of cash on hand, with Banks in current accounts and demand deposit.

8. Foreign Exchange Transactions:

There were no foreign exchange transactions during the year.

9. Changes in Accounting Policies:

Accounting Policies have been consistently applied where a newly issued Accounting Standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use, Management evaluates all recently issued or revised Accounting Standards on an ongoing basis and accordingly changes the Accounting Policies as applicable.

10. Taxes on Income:

Current tax determined based on the amount of tax payable in respect of taxable income for the period. Deferred tax is recognized on timing differences being the difference between the taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. During the current period the timing difference has arisen due to change in depreciation rates.

B) NOTES ON ACCOUNTS :**1. Remuneration To Auditors :**

Particulars	2009-10 Amount (Rs.)	2008-09 Amount (Rs.)
Audit Fees	66,180	33,090
Tax Audit	22,060	11,030
TOTAL	88,240	44,120

2. Accounting Standard 18 Related Party Disclosure:

As per Accounting Standard 18 issued by the Institute of Chartered Accountants of India, the company's related parties with whom the Company has entered into transactions during the year in the ordinary course of business, as certified by the Management are3 disclosed below.

Name of the Person	Relationship	Amount (Rs.)	Nature of Transaction
Arvind Kumar Bhangadia	Executive Director	2,40,000	Remuneration Paid
Arun Kumar Bhangadia	Chairman	3,00,000	Rent Paid
Jyothi Bhangadia	Directors' Relative	84,000	Rent Paid
Kiran Bhangadia	Directors' Relative	3,00,000	Rent Paid
TDPL Health Care (India) Ltd.	Company in Which Mr. Arun Kumar Bhangadia and Mr. Arvind Kumar Bhangadia, are Directors.	20,005,764	Medicines purchased from TDPL Helath Care (India) Ltd.
TDPL Health Care (India) Ltd.	Company in Which Mr. Arun Kumar Bhangadia and Mr. Arvind Kumar Bhangadia, are Directors.	25,82,300	Sale of Investments

- a) The Management of the Company feels that the Rent paid to above directors and their relatives was reasonable when compared to prevailing market prices in the similar areas.
- b) The Medicines Purchased from TDPL Health Care (India) Ltd.,M/s. TDPL Health Care (India) Ltd., is C&F Agent and the price paid for such medicines is reasonable when compared to prevailing market prices.

3. Earning Per Share:

Basic EPS before extraordinary items	0.10
Diluted EPS before extraordinary items	0.10

4. Segment Reporting :

As per the Accounting Standard -17 Segment Reporting is Furnished here under

Particulars	Amount (Rs.) 31.03.2010	Amount (Rs.) 31.03.2009
Revenue		
i) Pharma Business	409.86	423.55
ii) Financial Activity	42.58	42.97
iii) Investment Activity	25.94	10.53
iv) Trading in Shares	275.92	2737.11
TOTAL	754.30	3214.15
Results		
i) Pharma Business	14.80	(1.59)
ii) Financial Activity	38.87	42.97
iii) Investment Activity	2.12	3.91
iv) Trading in shares	35.06	1.04
TOTAL	90.85	46.33
Capital Employed		
i) Pharma Business	234.52	271.42
ii) Financial Activity	334.97	285.68
iii) Investment Activity	95.54	74.99
iv) Trading in shares	NIL	NIL
TOTAL	665.03	632.09

Note : In the segment reporting common assets that are used interchangeable not allocated to the individual segments above.

5. Provisions, Contingent Liabilities and Contingent Assets:

Provisions are recognised for liabilities that can be measured only by using a substantial degree of estimation, if the Company has a present obligation as a result of past event, a probable outflow of resource is expected to settle the obligation and the amount of obligation can be really estimated.

An amount of Rs.2,88,000/- has identified as a Contingent Liability on account of dispute in title of a Motor Car purchased by the Company. The Company has filed a case in the Hon'ble High Court of Andhra Pradesh which is pending for disposal.

Provisions, Contingent Liabilities and Contingent Assets are reviewed at each Balance sheet Date.

Provision for Income Tax includes an amount of Rs.91,068/- (Rupees Ninety One Thousand and Sixty Eight Only) towards Interest U/s 234B & C of Income Tax Act, 1961.

6. Accounting Standard 22- Accounting for Taxes on Income:

The deferred tax liability is arrived as under:

Particulars	31-03-2010	31-03-2009
Opening Deferred Tax Liability	19,25,627	16,43,214
Add/Less : Deferred Tax Asset / Liability on A/c of Deprectaion Difference	1,30,491	2,82,413
Closing Deffered Tax Liability	20,56,118	19,25,627

7. In the opinion of the Directors, Current Assets, Loans and Advances have the value at which they are stated in the Balance sheet, if realized in the ordinarily course of the Business.
8. Balances of Sundry Debtors, Loans and Advances are subject to confirmation.
9. The Company has made payments to units covered under Micro, Small and Medium Enterprises Development Act, 2006 in due time. There are no outstanding balances due to these Units at the closure of the accounting year.
10. Previous year figures have been regrouped and rearranged wherever found necessary, to be in confirmative with current year classification.
11. Paises are rounded off to the nearest rupee.
12. Schedules 1 to 10 form part an integral of this report.

As per our report of even date,

For K.VENKATESWARA RAO & ASSOCIATES,
Chartered Accountants,

for and on behalf of the Board,

CA. K.VENKATESWAR RAO,

Proprietor

Place : Hyderabad,

Date : 22nd July, 2010.

Managing Director.

Chairman

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

CASH FLOW STATEMENT FOR THE PERIOD ENDED 31ST MARCH, 2010 (Rs. In Lacs)

Particulars	As at 31.03.2010	As at 31.03.2009
A. Cash Flow from Operating Activities:		
Net Profit before Tax and Extraordinary items	90.85	47.74
Adjustment for:		
Depreciation	23.70	22.79
Interest & other Income	(52.12)	(51.13)
Operating profit before working capital changes	62.42	19.40
Adjustments for:		:
Trade and Other receivables	(45.90)	(146.45)
Inventories	(24.85)	60.36
Trade payable	(5.96)	26.41
Cash generated from operations	(76.72)	(59.68)
Cash flow before extra-ordinary items	(76.72)	(59.68)
Extraordinary items and Tax	(44.17)	(38.59)
Net Cash used for Operating activities	(58.46)	(78.87)
B. Cash flow from Investing Activities:		
Purchase of Fixed Assets	(31.65)	(14.60)
Sales of Fixed Assets	NIL	(0.34)
Increase in Investments	(55.55)	6.61
Decrease in Investments & Deposits	10.91	1.60
Interest and Other Income	52.11	51.13
Net Cash flow from Investing Activities	(24.18)	44.40
C. Cash flow from Financing Activities:		
Increase in Share Capital	NIL	NIL
Proceeds from Short Term Borrowings	2.42	20.14
Share Issue and Preliminary Expenses	NIL	NIL
Net Cash flow from Financing Activities	2.42	20.14
Net Increase in Cash and Cash equivalents	(80.22)	(14.33)
Cash and Cash equivalents as at (Opening Balance)	97.21	111.54
Cash and Cash equivalents as at (Closing Balance)	16.99	97.21

We have verified the above Cash Flow Statement of TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED, for the year ended on 31st March 2010, which has been derived from the audited annual accounts after making such adjustments / groupings as were considered appropriate and found the same to be true and correct.

As per our report of even date.

For K.Venkateswara Rao & Associates

For and on behalf of the Board

C.A.K.Venkateswara Rao
Proprietor

Place : Hyderabad
Date : 22nd July 2010

Arvind Kumar Bhangadia
Managing Director

Arun Kumar Bhangadia
Chairman
ISO 9001:2008 Company

**PART IV OF THE COMPANIES ACT, 1956 BALANCE SHEET
ABSTRACT AND COMPANY'S GENERAL BUSINESS PROFILE**

I REGISTRATION DETAILS :

Registration No.	: 18956	State Code	: 01
Balance Sheet Date	: 31.03.2010		

II CAPITAL RAISED DURING THE YEAR: (Rs in 000's)

a) Public Issue	: NIL	b) Bonus Issue	: NIL
c) Private Placement	: NIL	d) Rights Issue	: NIL

III POSITION OF MOBILISATION AND DEPLOYMENT OF FUNDS : (Rs in 000's)

Total Liabilities	: 80559	Total Assets	: 80559
-------------------	---------	--------------	---------

SOURCES OF FUNDS

Paid up Capital	: 67500
Share Application Money:	: NIL
Reserves & Surplus	: 8747
Secured Loans	: 2256
Deferred Tax	: 2056

APPLICATION OF FUNDS

Net Fixed Assets	: 18215
Investments	: 8054
Net Current Assets	: 54290
Misc. Expenditure	: NIL
Accumulated Losses	: NIL

IV. PERFORMANCE OF THE COMPANY (Amt in Rs.000's) :

Total Income	: 73789	Profit after Tax	: 6899
Total Expenditure	: 64704	Earning per Share(Rs.)	: 1.02
Profit before Tax	: 9085	Dividend Rate	: 03%

**V. GENERIC NAMES OF THREE PRINCIPAL PRODUCTS/SERVICES OF THE COMPANY
(AS PER MONETARY TERMS)**

Product Description : Trading & Marketing of Pharmaceutical products.

Vide our Reports of even Date For and on behalf of the Board

For K.Venkateswara Rao & Associates
Chartered Accountants

SD/- C.A K.Venkateswara Rao Proprietor	SD/- Arvind Kumar Bhangadia Managing Director	SD/- Arun Kumar Bhangadia Chairman
---	--	---

Place: Hyderabad.

Date : 23rd July 2010

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 4-4-231/1/2/ABC, Inderbagh, Sultan Bazar, Hyderabad-500 095.

ATTENDANCE SLIP

Name :

Folio No./Client ID :

Number of Shares :

I hereby record my presence at the 16th ANNUAL GENERAL MEETING of the Company at RGA Hall, Snatak Bhavan, 5-4-790/1, Ashirvad Complex, 1st Floor, Abids, Hyderabad – 500 001 on Monday the 30th day of August, 2010 at 11.00 A.M.

SIGNATURE OF THE ATTENDING MEMBER/PROXY

Note: Shareholder/Proxy holder wishing to attend the meeting must bring this Attendance Slip to the meeting and hand it over at the entrance duly signed.

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 4-4-231/1/2/ABC, Inderbagh, Sultan Bazar, Hyderabad-500 095.

PROXY

I/We.....of.....(address) being a Member/Members of Trimurthi Drugs & Pharmaceuticals Limited, do hereby appoint Mr./Ms.....of.....(address) as my/our proxy to attend and vote for me/us behalf at the 16th Annual General Meeting of the Company, to be held on Monday the 30th day of August, 2010 at 11.00 A.M and at any adjournment thereof.

Signed this.....day of2010

Regd. Folio No/Client ID.....

Affix
Revenue
Stamp

Number of Shares.....

Signature

Note: The Proxy must be deposited at the Registered Office of the Company not less than 48 hours before the time of the holding the Meeting. A proxy need not be a member.